Grupo Español de Investigación en Cáncer de Ovario
24
2
4
17
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
4.2%
1 terminated/withdrawn out of 24 trials
94.4%
+7.9% vs industry average
33%
8 trials in Phase 3/4
12%
2 of 17 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (24)
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Role: collaborator
PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
Role: collaborator
TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation
Role: lead
Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix
Role: lead
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]
Role: collaborator
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
Role: lead
Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer
Role: collaborator
Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer
Role: lead
Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer
Role: lead
ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer
Role: collaborator
DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial Cancer
Role: lead
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Role: collaborator
Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD
Role: lead
Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin
Role: lead
Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma
Role: lead
Platine, Avastin and OLAparib in 1st Line
Role: collaborator
Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
Role: collaborator
Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Role: lead
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Role: collaborator
Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin
Role: lead